Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.

NCT01425801 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: LAS100977 0.313 μg
DRUG: LAS100977 0.625 μg
DRUG: LAS100977 1.25 μg
DRUG: LAS100977 2.5 μg
DRUG: Salbutamol 400 μg
DRUG: Salbutamol placebo
DRUG: LAS100977 placebo

Sponsor

AstraZeneca